Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | Zendy

Vlado Perkovic | Zendy; Meg Jardine | Zendy; Bruce Neal | Zendy; Séverine Bompoint | Zendy; Hiddo J.L. Heerspink | Zendy; David M. Charytan | Zendy; Robert Edwards | Zendy; Rajiv Agarwal | Zendy; George L. Bakris | Zendy; Scott Bull | Zendy; Christopher P. Can | Zendy; George Capuano | Zendy; Pei-Ling Chu | Zendy; Dick de Zeeuw | Zendy; Tom Greene | Zendy; Adeera Levin | Zendy; Carol A. Pollock | Zendy; David C. Wheeler | Zendy; Yshai Yavin | Zendy; Hong Zhang | Zendy; Bernard Zinman | Zendy; Gary Meininger | Zendy; Barry M. Brenner | Zendy; Kenneth W. Mahaffey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Author(s) -

Vlado Perkovic,

Meg Jardine,

Bruce Neal,

Séverine Bompoint,

Hiddo J.L. Heerspink,

David M. Charytan,

Robert Edwards,

Rajiv Agarwal,

George L. Bakris,

Scott Bull,

Christopher P. Can,

George Capuano,

Pei-Ling Chu,

Dick de Zeeuw,

Tom Greene,

Adeera Levin,

Carol A. Pollock,

David C. Wheeler,

Yshai Yavin,

Hong Zhang,

Bernard Zinman,

Gary Meininger,

Barry M. Brenner,

Kenneth W. Mahaffey

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1811744

Subject(s) - canagliflozin , medicine , type 2 diabetes , diabetes mellitus , diabetic nephropathy , nephropathy , dapagliflozin , clinical trial , type 2 diabetes mellitus , endocrinology , intensive care medicine , pharmacology , urology

Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research